YEEDO News
-
GOOD NEWS丨Congratulations on the IND approval of[¹⁸F]BF₃-BPA Injection of BoomRay
On August 29,2023, BoomRay Pharmaceuticals (hereinafter referred to as "BoomRay") , the registered partner of Yeedo, received a notice from the CDE that [¹⁸ F] BF ₃ -BPA injection (BR-02) developed by BoomRay obtained IND approval. Yeedo warmly congratulates BoomRay!2023-08-31 -
GOOD NEWS | Congratulations on the market approval of Fulvestrant Injection of Hangzhou Jiuyuan assisted by Yeedo
On June 28, 2022, Yeedo, as the registered partner of Hangzhou Jiuyuan, successfully helped obtain the marketing approval of "Fluvestrant Injection"( a category 4 drug)!2022-07-11 -
GOOD NEWS | Yeedo's Considerate Services With Powerful Epidemic Prevention and Control
Under the reasonable arrangement and deployment of the leaders, we completed the projects entrusted by customers on time with good quality and quantity and kept our commitment to customers.2022-06-02 -
.jpg)
Congratulations on the successful holding of the 28th Lingnan Forum on Clinical Trials (the Advanced Class on Early Clinical Trials of Innovative Drugs)
Mrs. Huang Haiyan of yeedo shared the course "Learning experience and communication of clinical Pharmacology Research of Innovative Drugs and PK Research Guidelines for Patients with Renal insufficiency".2022-04-02 -
Zifa01 Tablets Project recruits patients with acute symptomatic deep vein thrombosis
A "multi-center, positive drug, parallel controlled phase II clinical trial to evaluate the effectiveness and safety of Zifa01 tablets in the treatment of acute symptomatic deep vein thrombosis" (NMPA batch number: 2016L01725) is carried out in about 30 research centers with the Chinese Academy of Medical Sciences and Peking Union Medical College Hospital as the team leader.2021-12-06 -
Taihu Pharmaceutical Innovation Conference, waiting for you to meet
Taihu Pharmaceutical Innovation Conference, waiting for you to meet2021-10-12
